Brief report · 29 Dec 2025
Conference abstractPublished 27 Aug 2018
Artificial nucleosides and nucleotides: Applications as diagnostic and therapeutic agents against cancer
Cleveland State University, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Temozolomide is a DNA damaging agent that is a frontline therapeutic agent against brain tumors including glioblastoma (GBM). Unfortunately, resistance to temozolomide occurs frequently, thus limiting the overall utility of the agent. Resistance can be caused by a variety of different cellular defects. However, an emerging mechanism of resistance reflects the ability to DNA polymerases to misreplicate DNA lesions that are left unrepaired. In this study, we provide evidence that the therapeutic efficacy of temozolomide can be significantly increased by co-administration of an artificial nucleoside, denoted as 5-nitroindolyl-2â??-deoxyriboside (5-NIdR), that efficiently and selectively inhibits the replication of DNA lesions generated by temozolomide. Conversion of 5-NIdR to the corresponding nucleoside triphosphate 5-NITP in vivo creates a potent inhibitor of several human DNA polymerases that can replicate damaged DNA. This inhibition accounts for the ability of 5-NIdR to synergize with temozolomide to increase apoptosis of tumor cells. In a murine xenograft model of GBM, treatment with temozolomide only delayed tumor growth while co-administering 5-NIdR with temozolomide caused complete tumor regression. Preliminary toxicology studies demonstrate that high doses of 5-NIdR do not produce the side effects typically observed with conventional nucleoside analogs such as fludarabine and gemcitabine. Collectively, these pre-clinical results demonstrate pharmacological proof of concept for the coordinate inhibition of translesion DNA synthesis as a strategy to improve chemotherapeutic responses in aggressive brain tumors.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Molecular Biology: Open Access.
Commentary · 29 Dec 2025
Molecular Insights: Advancing Biology and Therapeutics
Brief report · 29 Dec 2025
Advancing Molecular Visualization and Understanding
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMolecular Biology: Open Access
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Anthony Berdis”
